1. Scrip
  2. >>Leadership

Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval

 
• By Kevin Grogan

The small interference RNA therapeutic can be used by patients regardless of inhibitor status.

Hemophilia World Day. Doctor With Donor Blood Drop
• Source: Shutterstock

The hemophilia market is a challenging and competitive field but Sanofi is confident that fitusiran, which has just been given the green light by the US Food and Drug Administration (28 March), has the potential to change the disease landscape thanks to the therapy’s effective bleed protection, infrequent dosing and easy administration.

Key Takeaways
  • Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
  • The antithrombin-lowering subcutaneous...

The agency has approved fitusiran, which will be marketed as Qfitlia, as the first antithrombin (AT)-lowering therapy for routine prophylaxis to prevent or reduce the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Interviews

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.